Ensign Peak Advisors
OLMA icon

Ensign Peak Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Ensign Peak Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-96,782
Closed -$1.44M – 1743
2026
Q1 		$1.44M Buy
+96,782
New +$2.15M ﹤0.01% 771
2025
Q1 		– Sell
-18,849
Closed -$110K – 1713
2024
Q4 		$110K Hold
18,849
– – ﹤0.01% 1702
2024
Q3 		$225K Buy
18,849
+4,000
+27% +$51.1K ﹤0.01% 1687
2024
Q2 		$161K Buy
14,849
+850
+6% +$9.22K ﹤0.01% 1701
2024
Q1 		$158K Buy
+13,999
New +$181K ﹤0.01% 1713
2021
Q3 		– Sell
-9,800
Closed -$275K – 1870
2021
Q2 		$275K Buy
9,800
+3,200
+48% +$91.1K ﹤0.01% 1686
2021
Q1 		$219K Buy
+6,600
New +$283K ﹤0.01% 1721

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Ensign Peak Advisors's OLMA Position: Q2 2026 in Review

Ensign Peak Advisors sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 96,782 shares — an estimated $1.44M sold.

Ensign Peak Advisors first reported a position in OLMA in Q1 2021 and held it in 7 quarters. The position peaked at $1.44M in Q1 2026. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Ensign Peak Advisors reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 96,782 Olema Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Ensign Peak Advisors first reported a position in Olema Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Ensign Peak Advisors's Olema Pharmaceuticals position peaked at $1.44M in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.